Evidence map›Paper›PMID 28068959›Full record

ArticleBMC cancer2017

Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report.

Yasunaru Sakuma, Yoshikazu Yasuda, Naohiro Sata, Yoshinori Hosoya, Atsushi Shimizu, Hirofumi Fujii, Daisuke Matsubara, Noriyuki Fukushima, Atsushi Miki, Misato Maeno and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yasunaru SakumaDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Yoshikazu YasudaDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Naohiro SataDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Yoshinori HosoyaDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Atsushi ShimizuDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Hirofumi FujiiDepartment of Oncology, Jichi Medical University, Tochigi, Japan.
Daisuke MatsubaraDepartment of Pathology, Jichi Medical University, Tochigi, Japan.
Noriyuki FukushimaDepartment of Pathology, Jichi Medical University, Tochigi, Japan.
Atsushi MikiDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Misato MaenoDepartment of Surgery, Jichi Medical University, Tochigi, Japan.
Alan Kawarai LeforDepartment of Surgery, Jichi Medical University, Tochigi, Japan. alefor@jichi.ac.jp.
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term term survival in patients with pancreatic neuroendocrine tumors has been reported, even in patients with metastatic disease. Metastases to the spleen are extremely rare, but have been reported from a number of primary malignancies, such as breast cancer, lung cancer, melanoma and ovarian cancer. This is the first report of a splenic metastasis from a primary pancreatic neuroendocrine tumor. CASE PRESENTATION: The patient presented as a 53 years old white male with anemia and fatigue. Physical examination revealed a left upper quadrant fullness and computed tomography showed a 24 cm left upper quadrant mass with multiple liver metastases, splenomegaly and a 1 cm mass in the spleen. Resection of the primary pancreatic tumor (T4N0M1) was accompanied by gastrectomy, splenectomy and resection of adherent bowel. The spleen contained a metastatic lesion 1.0 cm in diameter, consistent with a primary neuroendocrine tumor of the pancreas. This operation was followed 8 months later, by delayed resection of liver metastases. The patient receives monthly administration of somatostatin long-acting analogue and has undergone several ablations of liver lesions with percutaneous radiofrequency ablation as well as a second liver resection. The patient is alive seven years after initial presentation, with no evidence of disease on imaging studies.

conclusionsThis is the first report of a splenic metastasis from a primary pancreatic neuroendocrine tumor. The patient initially presented with synchronous multiple liver metastases and a single splenic metastasis. After resection of the primary tumor and spleen, the patient has undergone aggressive cytoreductive surgery/ablation of liver lesions and somatostatin therapy with resulting long-term survival.

Indexed as

HumansMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsPrognosisSplenic NeoplasmsCase reportLiver metastasisPancreatic neuroendocrine tumorRadiofrequency ablationSomatostatinSpleen metastasis

Identifiers

PMID28068959
PMCPMC5223534
OpenAlexW2570091420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.